China Drugmakers Advance on H1N1, Industry Plan: Shanghai Mover

Chinese health-care shares rose the most in two weeks on speculation medicine demand will increase after two women died from the H1N1 flu strain in Beijing and the government set targets for growth in the biomedical industry.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.